• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 8-K filed by Pulmatrix Inc.

    4/8/25 4:05:29 PM ET
    $PULM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PULM alert in real time by email
    false 0001574235 0001574235 2025-04-04 2025-04-04 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

     

    FORM 8-K

     

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the

    Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): April 4, 2025

     

     

     

    PULMATRIX, INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   001-36199   46-1821392

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

     

    945 Concord Street, Suite 1217

    Framingham, MA 01701

    (Address of principal executive offices) (Zip Code)

     

    (888) 355-4440

    (Registrant’s telephone number, including area code)

     

    N/A

    (Former name or former address, if changed since last report)

     

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of exchange on which registered
    Common Stock, par value $0.0001 per share   PULM   The NASDAQ Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 5.07

    Changes In Registrant’s Certifying Accountant.

     

    (a) Resignation of Independent Registered Public Accounting Firm

     

    On April 4, 2025, Pulmatrix, Inc. (the “Company”) was notified by Marcum LLP (“Marcum”) that Marcum resigned as the independent registered accounting firm of the Company. On November 1, 2024, CBIZ CPAs P.C. (“CBIZ”) acquired the attest business of Marcum. Substantially all of the partners and staff that provided attestation services with Marcum joined CBIZ CPAs P.C. On April 4, 2025, Marcum resigned as auditors of the Company and with the approval of the Audit Committee of the Company’s Board of Directors, CBIZ was engaged as the Company’s independent registered public accounting firm.

     

    The reports of Marcum on the Company’s consolidated financial statements for the years ended December 31, 2024, and December 31, 2023, did not contain an adverse opinion or a disclaimer of opinion, and was not qualified or modified as to uncertainty, audit scope, or accounting principles.

     

    During the two most recent fiscal years ended December 31, 2024, and December 31, 2023, and the subsequent interim period through April 4, 2025, there were no disagreements (as defined in Item 304(a)(1)(iv) of Regulation S-K of the Securities Exchange Act of 1934, as amended (“Regulation S-K”) and the related instructions to Item 304 of Regulation S-K) with Marcum on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of Marcum, would have caused Marcum to make reference to the subject matter of the disagreements in connection with its reports on the Company’s consolidated financial statements for such years. Also during this time, there were no “reportable events,” as defined in Item 304(a)(1)(v) of Regulation S-K.

     

    The Company provided Marcum with a copy of the above disclosures and requested that Marcum furnish the Company with a letter addressed to the Securities and Exchange Commission stating whether or not it agrees with the statements made above. A copy of Marcum’s letter dated April 8, 2025, is attached as Exhibit 16.1 to this Current Report on Form 8-K.

     

    (b) Engagement of New Independent Registered Public Accounting Firm

     

    On April 4, 2025, the Audit Committee engaged CBIZ as the Company’s independent registered public accounting firm for the fiscal year ended December 31, 2025. In connection with the engagement, CBIZ will prepare the report on the Company’s consolidated financial statements for the year ending December 31, 2025. During the fiscal years ended December 31, 2024, and December 31, 2023, and the subsequent interim period through April 4, 2025, neither the Company nor anyone on its behalf has consulted with CBIZ regarding (i) the application of accounting principles to any specified transaction, either completed or proposed or the type of audit opinion that might be rendered on the Company’s consolidated financial statements, and neither a written report nor oral advice was provided to the Company that CBIZ concluded was an important factor considered by the Company in reaching a decision as to any accounting, auditing, or financial reporting issue, or (ii) any matter that was either the subject of a “disagreement,” as defined in Item 304(a)(1)(iv) of Regulation S-K, or a “reportable event,” as defined in Item 304(a)(1)(v) of Regulation S-K.

     

    Item 9.01 Financial Statements and Exhibits.

     

    (d) Exhibits.

     

    Exhibit
    Number
      Description of Exhibit
    16.1   Letter from Marcum LLP to the Securities and Exchange Commission dated April 8, 2025
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      PULMATRIX, INC.
         
    Date: April 8, 2025 By: /s/ Peter Ludlum
        Peter Ludlum
        Interim Chief Executive Officer

     

     

     

    Get the next $PULM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PULM

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PULM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Pulmatrix Inc. (Amendment)

      SC 13G/A - Pulmatrix, Inc. (0001574235) (Subject)

      1/2/24 9:42:57 AM ET
      $PULM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Pulmatrix Inc. (Amendment)

      SC 13G/A - Pulmatrix, Inc. (0001574235) (Subject)

      2/8/23 6:08:04 AM ET
      $PULM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Pulmatrix Inc. (Amendment)

      SC 13G/A - Pulmatrix, Inc. (0001574235) (Subject)

      1/10/23 11:21:19 AM ET
      $PULM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PULM
    Leadership Updates

    Live Leadership Updates

    See more
    • Pulmatrix appoints Director Anand Varadan

      LEXINGTON, Mass., July 27, 2021 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology, today announced the appointment of Anand Varadan to its Board of Directors, effective July 26, 2021. Mr. Varadan brings expertise in commercialization and successful product launches. In addition, Mark Iwicki stepped down from his role on the Board of Directors effective July 23, 2021. "We are delighted to welcome Anand to

      7/27/21 10:00:00 AM ET
      $PULM
      $CHMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Major Pharmaceuticals

    $PULM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Pulmatrix Announces Year-End and Fourth Quarter 2024 Financial Results and Divestment Plan for Assets

      Announced merger agreement with Cullgen in November, anticipated to close in the first half of 2025 As part of proposed merger, Pulmatrix intends to divest its assets including its Phase 2-ready acute migraine candidate, PUR3100, and other development candidates based on its iSPERSE™ technology FRAMINGHAM, Mass., March 21, 2025 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (NASDAQ:PULM), a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented iSPERSE™ technology, today announced fourth quarter and year-end financi

      3/21/25 8:05:00 AM ET
      $PULM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cullgen Begins Phase 1 Dosing of its Potential First-in-Class, Oral Pan-TRK Protein Degrader for Acute and Chronic Pain

      SAN DIEGO, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Cullgen Inc. ("Cullgen"), a privately-held, clinical-stage biopharmaceutical company applying its proprietary targeted protein degradation uSMITE™ platform to discover and advance therapeutics for the treatment of cancer and other diseases, today announced that it has begun dosing in human subjects to evaluate its potential first-in-class, oral, pan-TRK protein degrader for the treatment of pain. CG001419 is a highly active small molecule designed to selectively degrade both mutant and wild-type TRK proteins and is being developed to be a new, non-opioid, non-NSAID analgesic therapy as part of a new class of pain signal inhibitors that have the

      1/22/25 8:00:00 AM ET
      $PULM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pulmatrix and Cullgen Announce Proposed Merger

      Merger to create a Nasdaq-listed company focusing on targeted protein degradation technology with three degrader programs in or about to initiate Phase 1 clinical trials – two for the treatment of cancer and one for the treatment of acute and chronic pain Combined company expected to have approximately $65 million of cash and cash equivalents at close to provide funding through multiple clinical milestones and expected runway through 2026 As part of merger agreement, Pulmatrix intends to divest its assets including its acute migraine candidate, PUR3100, and other development candidates based on its iSPERSE™ technology Cullgen and Pulmatrix will host an informational webcast about the propose

      11/13/24 9:00:00 AM ET
      $PULM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PULM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $PULM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • HC Wainwright & Co. reiterated coverage on Pulmatrix with a new price target

      HC Wainwright & Co. reiterated coverage of Pulmatrix with a rating of Buy and set a new price target of $5.00 from $10.00 previously

      4/13/21 6:23:02 AM ET
      $PULM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Batycky Richard P.

      4 - Pulmatrix, Inc. (0001574235) (Issuer)

      1/30/23 4:05:40 PM ET
      $PULM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Varadan Anand

      4 - Pulmatrix, Inc. (0001574235) (Issuer)

      1/30/23 4:05:42 PM ET
      $PULM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Cabell Christopher

      4 - Pulmatrix, Inc. (0001574235) (Issuer)

      1/30/23 4:05:43 PM ET
      $PULM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PULM
    SEC Filings

    See more
    • SEC Form 424B3 filed by Pulmatrix Inc.

      424B3 - Pulmatrix, Inc. (0001574235) (Filer)

      5/9/25 4:55:25 PM ET
      $PULM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form S-4/A filed by Pulmatrix Inc.

      S-4/A - Pulmatrix, Inc. (0001574235) (Filer)

      5/6/25 9:51:14 PM ET
      $PULM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form S-4/A filed by Pulmatrix Inc.

      S-4/A - Pulmatrix, Inc. (0001574235) (Filer)

      4/17/25 8:39:23 AM ET
      $PULM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PULM
    Financials

    Live finance-specific insights

    See more
    • Pulmatrix Announces Year-End and Q4 Financial 2022 Results and Provides Corporate Update

      PUR1900 Phase 2b study dosed first patients in Q1 2023 PUR3100 Phase 1 study achieves positive topline results as announced in Q1 2023 $35.6 million in cash and cash equivalents at the end of 2022 providing cash runway into Q2 2024 LEXINGTON, Mass., March 30, 2023 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ:PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and central nervous system disease using its patented iSPERSE™ technology, today announced fourth quarter and year-end financial results for 2022 and provided a corporate update on its development programs.

      3/30/23 9:05:00 AM ET
      $PULM
      Biotechnology: Pharmaceutical Preparations
      Health Care